Jagsonpal Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 April 2026.

Jagsonpal Pharmaceuticals has allotted 1,76,900 equity shares under ESOP on 13 April 2026. With this allotment, the paid up equity share capital has increased to Rs. 13,42,78,300 (constituting of 6,71,39,150 equity shares of Rs. 2/- each).

The Board of Jagsonpal Pharmaceuticals at its meeting held on 12 March 2026 approved a proposal to buyback up to 16,00,000 fully paid-up equity shares of the company at a price of Rs 250 per equity shares (a premium of through Tender Offer method, subject to shareholders approval. This represents 2.4% of the total equity shares of the Company and 7.3% of the non-promoter shareholding of the company. The proposed buyback will be undertaken for an aggregate amount not exceeding Rs 40 crore, representing ~18.4% of the company's total paid-up equity share capital and free reserves based on the latest audited financial statements as of 31 March 2025.

Powered by Capital Market - Live News

The board approved the buyback of upto Rs 16 lakh equity shares, representing 2.39% of total outstanding equity shares. The buyback will be carried out at a price of Rs 250 per share, aggregating to a maximum outlay of Rs 40 crore.

The buyback price represents a premium of 39.74% over the previous day?s closing price of Rs 178.90 on the BSE.

The company?s promoter and promoter group shareholding stood at 67.2% prior to the buyback and is expected to increase to 68.9% post buyback.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company?s standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.

Powered by Capital Market - Live News